Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma

Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma

Shen-Cun Fang,1,2 Hai-Tao Zhang,1 Ying-Ming Zhang,1 Wei-Ping Xie2 1Department of Respiratory Medicine Center, Nanjing Chest Hospital, 2Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, People’s Republic of...

Full description

Bibliographic Details
Main Authors: Fang S, Zhang H, Zhang Y, Xie W
Format: Article
Language:English
Published: Dove Medical Press 2017-01-01
Series:OncoTargets and Therapy
Subjects:
Non-small-cell lung cancer
angiogenesis
Apatinib
VEGFR-2
Online Access:https://www.dovepress.com/apatinib-as-post-second-line-therapy-in-egfr-wild-type-and-alk-negativ-peer-reviewed-article-OTT

Internet

https://www.dovepress.com/apatinib-as-post-second-line-therapy-in-egfr-wild-type-and-alk-negativ-peer-reviewed-article-OTT

Similar Items